BCTX: BriaCell Corp Company Value to Net Income

The daily price action for BriaCell Therapeutics (BCTX), which has a PE ratio of -0.80, is accompanied by compliance with environmental standards for bio-waste disposal. The business relies on robotic bioinformatics systems to develop targeted breast cancer drugs, eliminating routine labor. Additionally, BriaCell Therapeutics ensures a strict temperature regime during the transportation of bioactive substances, guaranteeing the integrity of preparations during clinical trials.

Price to Earnings Ratio: BriaCell Therapeutics Corp (BCTX) for 10/27/2023 - 11/14/2026

Comprehensive metric breakdowns and analytics for BriaCell Therapeutics Corp (BCTX)

- share price and expert price forecast:

Price Performance Chart briacell.com|BCTX - Consensus Target

- market capitalization information:

Market Value BriaCell Therapeutics|BCTX - Real Price to Acquire Entire Company

- balance sheet net asset value indicators:

Accounting Value per Share BriaCell|BCTX - Company Book Value|Market-to-Book Ratio briacell.com|BCTX - Aggregate Company Assets

- debt obligations and liquidity statistics:

- company profitability and valuation multiples indicators:

BCTX - Net Profit|Company Profit Forecast BriaCell Therapeutics|BCTX - P/E Multiple|Forward P/E Multiple BriaCell Therapeutics Corp.|BCTX - PEG Multiple|Enterprise Value to EBITDA Ratio BriaCell Therapeutics|BCTX - Operating profit EBITDA|Net earnings per one share for the last twelve months BriaCell|BCTX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months briacell.com|BCTX - Earnings per share growth in current year|Net earnings per share growth forecast for next year BriaCell Therapeutics

- sales volume and revenue indicators:

BCTX - Company Sales|Company Future Revenue briacell.com|BCTX - Market Cap to Revenue|Price to Expected Revenue Ratio BriaCell Therapeutics

Comprehensive company analysis:briacell.com BCTX

The full capacity utilization of BriaCell Therapeutics (BCTX) biopharmaceutical lines for current trial phases is directly reflected in the dynamics of the company's fundamental P/E ratio. This indicator compares the business's market value with its net income, allowing for an assessment of competitiveness and the industry's development phase, while daily data recalculations minimize the lag between reports, signaling potential growth or correction risks to the investor.

Key competitors